Skip to main content

Imperial Equities Inc. Appoints Dr. Dennis Modry to Board of Directors

By June 3, 2008July 13th, 2019No Comments

EDMONTON, ALBERTA – Mr. Sine Chadi, Chairman of the Board of Imperial Equities Inc. (TSX-V:IEI) is pleased to announce that Dr. Dennis Modry has been appointed a director of Imperial Equities Inc.

Dr. Modry implemented Western Canada’s first heart and lung transplantation program. He performed the first heart transplant in July 1985 and the first combined transplant of the heart with both lungs in August 1986. The heart and heart/lung transplantation program has now become the largest and most successful in Canada and one of the largest in North America. The success of the heart and lung transplant program set the stage for the implementation of the liver transplantation program which facilitated the subsequent development of the renowned islet cell transplant program.

Dr. Dennis Modry, BSc, MD, FRCS(C), FACCP, FACS, received his B.Sc. and M.D. Degrees from the University of Alberta and his M.Sc. Degree and training in General Surgery and Cardiovascular and Thoracic Surgery at McGill University. Before returning back to Alberta, he further trained in transplantation immunology, heart and lung transplantation and cardiovascular surgery at Stanford University Medical Centre.

“We are extremely pleased to have someone with Dr. Modry’s experience on the Board of Imperial,” said Sine Chadi. “Imperial Distributors Canada Inc., our pharmaceutical distribution business, has experienced rapid growth during the past 24 months and we certainly welcome his medical expertise. He is also very involved in many community endeavors and serves on numerous hospital committees. Dr. Modry will be a tremendous addition to the Imperial Board”.

Dr. Modry’s appointment succeeds Mr. Bill Smith who recently resigned from the Board to concentrate on his personal business interests. The Board wishes Mr. Smith great success in his future endeavors and thanks him for his contributions to the Board. Dr. Modry’s appointment has been approved by the Board and is subject to regulatory approval.